What does CUSIP 492327101 represent in this 13F holders report?

CUSIP 492327101 is the security identifier for KROS - Keros Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held KROS - Keros Therapeutics, Inc. - Common Stock in Q2 2023?

121 institutional investors reported KROS - Keros Therapeutics, Inc. - Common Stock for Q2 2023. Use the holders table for investor-level position and value details.

Keros Therapeutics, Inc. - Common Stock (KROS)

CUSIP: 492327101

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock
Shares outstanding: 19,711,307
Total 13F shares: 22,423,232
Share change: +419,994
Total reported value: $900,980,099
Put/Call ratio: 3.9%
Price per share: $40.18
Number of holders: 121
Value change: +$13,493,306
Number of buys: 73
Number of sells: 47

Quarterly Holders Quick Answers

What is CUSIP 492327101?
CUSIP 492327101 identifies KROS - Keros Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2023
Previous quarter: Q1 2023

Recent filing periods for CUSIP 492327101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of KROS - Keros Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	21%	4,051,873	$173,014,977	—	31 Mar 2023	13F
ORBIMED ADVISORS LLC	13F	Company	8.5%	1,679,417	$71,711,106	—	31 Mar 2023	13F
ALKEON CAPITAL MANAGEMENT LLC	13F	Company	8.5%	1,678,018	$71,651,368	—	31 Mar 2023	13F
BlackRock Finance, Inc.	13F	Company	8.5%	1,677,260	$71,619,004	—	31 Mar 2023	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	5.8%	1,152,516	$49,213,000	—	31 Mar 2023	13F
VANGUARD GROUP INC	13F	Company	5.3%	1,048,062	$44,752,247	—	31 Mar 2023	13F
STATE STREET CORP	13F	Company	4.8%	944,159	$40,315,531	—	31 Mar 2023	13F
Paradigm Biocapital Advisors LP	13F	Company	4.7%	930,752	$39,743,110	—	31 Mar 2023	13F
Nantahala Capital Management, LLC	13F	Company	3.8%	742,819	$31,718,371	—	31 Mar 2023	13F
S.c.a. Candriam	13F	Individual	3.8%	745,057	$29,282,543	—	31 Mar 2023	13F
First Light Asset Management, LLC	13F	Company	3%	593,964	$25,362,263	—	31 Mar 2023	13F
Yiheng Capital Management, L.P.	13F	Company	2.8%	554,151	$23,662,248	—	31 Mar 2023	13F
FRANKLIN RESOURCES INC	13F	Company	2.4%	472,751	$20,186,468	—	31 Mar 2023	13F
CITADEL ADVISORS LLC	13F	Company	1.9%	371,483	$15,862,324	—	31 Mar 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.9%	368,046	$15,715,564	—	31 Mar 2023	13F
CITIGROUP INC	13F	Company	1.7%	326,064	$13,922,933	—	31 Mar 2023	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	1.5%	300,000	$12,810,000	—	31 Mar 2023	13F
Clal Insurance Enterprises Holdings Ltd	13F	Company	1.5%	299,000	$12,767,000	—	31 Mar 2023	13F
CHI Advisors LLC	13F	Company	1.3%	261,059	$11,147,219	—	31 Mar 2023	13F
Opaleye Management Inc.	13F	Company	1.2%	238,000	$10,162,600	—	31 Mar 2023	13F
Point72 Asset Management, L.P.	13F	Company	1%	205,660	$8,781,682	—	31 Mar 2023	13F
Woodline Partners LP	13F	Company	1%	198,139	$8,460,535	—	31 Mar 2023	13F
Parkman Healthcare Partners LLC	13F	Company	0.91%	179,290	$7,655,683	—	31 Mar 2023	13F
NORTHERN TRUST CORP	13F	Company	0.9%	177,270	$7,569,429	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	0.72%	140,970	$6,019,420	—	31 Mar 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.67%	132,768	$5,669,194	—	31 Mar 2023	13F
Bank of New York Mellon Corp	13F	Company	0.67%	132,577	$5,661,039	—	31 Mar 2023	13F
Soleus Capital Management, L.P.	13F	Company	0.62%	122,316	$5,222,893	—	31 Mar 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.61%	121,100	$5,171,000	—	31 Mar 2023	13F
MARSHALL WACE, LLP	13F	Company	0.59%	116,520	$4,975,404	—	31 Mar 2023	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.57%	113,143	$4,821,906	—	31 Mar 2023	13F
Jennifer Lachey	3/4/5	Chief Scientific Officer	— mixed-class rows	103,855 mixed-class rows	$4,307,079	—	15 Jul 2022	3/4/5
DEUTSCHE BANK AG\	13F	Company	0.44%	87,396	$3,731,809	—	31 Mar 2023	13F
WCM INVESTMENT MANAGEMENT, LLC	13F	Company	0.43%	84,026	$3,587,910	—	31 Mar 2023	13F
Sofinnova Investments, Inc.	13F	Company	0.39%	77,100	$3,292,170	—	31 Mar 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.38%	75,669	$3,231,066	—	31 Mar 2023	13F
VOYA INVESTMENT MANAGEMENT LLC	13F	Company	0.36%	70,184	$2,996,857	—	31 Mar 2023	13F
Walleye Capital LLC	13F	Company	0.34%	67,636	$2,888,057	—	31 Mar 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.34%	67,169	$2,868,000	—	31 Mar 2023	13F
Rafferty Asset Management, LLC	13F	Company	0.32%	63,031	$2,691,424	—	31 Mar 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.32%	62,260	$2,658,502	—	31 Mar 2023	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.29%	56,545	$2,414,471	—	31 Mar 2023	13F
Russell Investments Group, Ltd.	13F	Company	0.28%	55,586	$2,373,521	—	31 Mar 2023	13F
Integral Health Asset Management, LLC	13F	Company	0.25%	50,000	$2,135,000	—	31 Mar 2023	13F
CIBC Asset Management Inc	13F	Company	0.24%	47,304	$2,019,881	—	31 Mar 2023	13F
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	13F	Company	0.23%	45,484	$1,942,167	—	31 Mar 2023	13F
Qube Research & Technologies Ltd	13F	Company	0.19%	37,611	$1,605,990	—	31 Mar 2023	13F
Swiss National Bank	13F	Company	0.18%	35,700	$1,524,390	—	31 Mar 2023	13F
UBS Group AG	13F	Company	0.17%	33,051	$1,411,278	—	31 Mar 2023	13F
Darwin Global Management, Ltd.	13F	Company	0.16%	31,386	$1,340,182	—	31 Mar 2023	13F

Institutional Holders of Keros Therapeutics, Inc. - Common Stock (KROS) as of Q2 2023

As of 30 Jun 2023, Keros Therapeutics, Inc. - Common Stock (KROS) was held by 121 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 22,423,232 shares. The largest 10 holders included FMR LLC, BlackRock Inc., ALKEON CAPITAL MANAGEMENT LLC, ORBIMED ADVISORS LLC, PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, BRAIDWELL LP, STATE STREET CORP, Candriam S.C.A., and EVENTIDE ASSET MANAGEMENT, LLC. This page lists 121 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

128

Q2 2023 holders

121

Holder diff

-7

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.